Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review.

Roselene Mesquita Augusto Passos Tallys Kalynka Feldens Miriam Allein Zago Marcolino Aline Sampaio Gouvêa Lais Dos Santos Oliveira Luisa Menardi Nasser Roseli Fernandes Rodrigues Leila de Lourdes Martins Perobelli Alessandro Gonçalves Campolina Cesar de Almeida Neto

Published in: Expert review of pharmacoeconomics & outcomes research (2022)

Plerixafor is a potentially cost-effective technology in the mobilization of HSC in patients with multiple myeloma and lymphomas eligible for autologous HSC transplantation. There is a decreased number of leukapheresis sessions and remobilizations and a higher yield of CD34+ cells.

Keyphrases

cell therapy
stem cells
bone marrow
multiple myeloma
induced apoptosis
cell cycle arrest
mesenchymal stem cells
platelet rich plasma
signaling pathway
endoplasmic reticulum stress
nk cells